NASDAQ:MESO - Mesoblast Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.17 -0.02 (-0.39 %) (As of 05/19/2019 04:00 PM ET)Previous Close$5.17Today's Range$5.1040 - $5.2052-Week Range$3.35 - $8.78Volume18,669 shsAverage Volume35,774 shsMarket Capitalization$486.86 millionP/E RatioN/ADividend YieldN/ABeta1.79 ProfileAnalyst RatingsChartEarningsInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia. Receive MESO News and Ratings via Email Sign-up to receive the latest news and ratings for MESO and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MESO Previous SymbolOTCMKTS:MBLTY CUSIPN/A CIKN/A Webwww.mesoblast.com Phone61-3-9639-6036Debt Debt-to-Equity Ratio0.12 Current Ratio2.89 Quick Ratio2.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$17.34 million Price / Sales28.08 Cash FlowN/A Price / Cash FlowN/A Book Value$5.80 per share Price / Book0.89Profitability EPS (Most Recent Fiscal Year)($0.63) Net Income$-35,290,000.00 Net Margins-528.80% Return on Equity-15.98% Return on Assets-12.53%Miscellaneous EmployeesN/A Outstanding Shares94,170,000Market Cap$486.86 million Next Earnings Date5/30/2019 (Estimated) OptionableOptionable Mesoblast (NASDAQ:MESO) Frequently Asked Questions What is Mesoblast's stock symbol? Mesoblast trades on the NASDAQ under the ticker symbol "MESO." How were Mesoblast's earnings last quarter? Mesoblast limited (NASDAQ:MESO) posted its quarterly earnings results on Wednesday, February, 20th. The company reported ($0.25) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.06. The business earned $1.87 million during the quarter, compared to analysts' expectations of $6.36 million. Mesoblast had a negative return on equity of 15.98% and a negative net margin of 528.80%. View Mesoblast's Earnings History. When is Mesoblast's next earnings date? Mesoblast is scheduled to release their next quarterly earnings announcement on Thursday, May 30th 2019. View Earnings Estimates for Mesoblast. What price target have analysts set for MESO? 4 analysts have issued 12-month target prices for Mesoblast's shares. Their predictions range from $6.50 to $23.00. On average, they expect Mesoblast's share price to reach $15.1250 in the next year. This suggests a possible upside of 192.6% from the stock's current price. View Analyst Price Targets for Mesoblast. What is the consensus analysts' recommendation for Mesoblast? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mesoblast in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mesoblast. What are Wall Street analysts saying about Mesoblast stock? Here are some recent quotes from research analysts about Mesoblast stock: 1. Maxim Group analysts commented, "Mesoblast announced that the FDA has agreed to a rolling review of the BLA for Remestemcel-L in pediatric steroid-refractory aGvHD. The company intends to begin the submission process soon." (4/16/2019) 2. According to Zacks Investment Research, "Mesoblast Limited is a global leader in developing innovative cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast's allogeneic, 'off-the-shelf' cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncologic/hematologic conditions. " (4/3/2019) 3. HC Wainwright analysts commented, "We maintain our Buy rating of MESO with a 12-month price target of $6.50 per diluted share. We derive our price target based on an NPV analysis of projected product revenues through FY2030. We assume a 12.2% discount rate, formulated by our calculation of Mesoblast’s weighted average cost of capital, and 3% terminal growth rate. We derive an NPV of $1.1B and add in pro forma net cash of $28.5M to arrive at a 12-month price target of $6.62, which we round to $6.50. (1) commercial; (2) partnership; (3) clinical; (4) financial; and (5) intellectual property." (2/22/2019) Has Mesoblast been receiving favorable news coverage? News articles about MESO stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Mesoblast earned a news impact score of 1.9 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 4.0 out of 10, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. Who are some of Mesoblast's key competitors? Some companies that are related to Mesoblast include Iovance Biotherapeutics (IOVA), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Regenxbio (RGNX), Orchard Therapeutics (ORTX), Alector (ALEC), Momenta Pharmaceuticals (MNTA), Coherus Biosciences (CHRS), Rubius Therapeutics (RUBY), Fate Therapeutics (FATE), Sangamo Therapeutics (SGMO), Atara Biotherapeutics (ATRA), Editas Medicine (EDIT), NanoString Technologies (NSTG) and Autolus Therapeutics (AUTL). What other stocks do shareholders of Mesoblast own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mesoblast investors own include Exelixis (EXEL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Portola Pharmaceuticals (PTLA), Progenics Pharmaceuticals (PGNX), Sangamo Therapeutics (SGMO), ADMA Biologics (ADMA) and Conatus Pharmaceuticals (CNAT). Who are Mesoblast's key executives? Mesoblast's management team includes the folowing people: Dr. Silviu Itescu, Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director (Age 62)Dr. Donna L. Skerrett, Chief Medical Officer (Age 62)Mr. Roger D. Brown BA, Head of Spinal Orthopedic DisordersMr. Michael Schuster MS, BSc, MBA, Head of Pharma Partnering (Age 42)Dr. Kenneth M. Borow M.D., Exec. (Age 71) When did Mesoblast IPO? (MESO) raised $69 million in an initial public offering (IPO) on Friday, November 13th 2015. The company issued 5,700,000 shares at $12.10 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Maxim Group and Ladenburg Thalmann were co-managers. Who are Mesoblast's major shareholders? Mesoblast's stock is owned by a number of of retail and institutional investors. Top institutional investors include Penbrook Management LLC (0.24%), Renaissance Technologies LLC (0.13%), Princeton Capital Management LLC (0.11%), Morgan Stanley (0.04%), Wells Fargo & Company MN (0.03%) and Jane Street Group LLC (0.02%). Which major investors are selling Mesoblast stock? MESO stock was sold by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Penbrook Management LLC, Princeton Capital Management LLC and Morgan Stanley. Which major investors are buying Mesoblast stock? MESO stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC and Wells Fargo & Company MN. How do I buy shares of Mesoblast? Shares of MESO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mesoblast's stock price today? One share of MESO stock can currently be purchased for approximately $5.17. How big of a company is Mesoblast? Mesoblast has a market capitalization of $486.86 million and generates $17.34 million in revenue each year. The company earns $-35,290,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. What is Mesoblast's official website? The official website for Mesoblast is http://www.mesoblast.com. How can I contact Mesoblast? Mesoblast's mailing address is LEVEL 38 55 COLLINS STREET, MELBOURNE C3, 3000. The company can be reached via phone at 61-3-9639-6036 or via email at [email protected] MarketBeat Community Rating for Mesoblast (NASDAQ MESO)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 295 (Vote Outperform)Underperform Votes: 174 (Vote Underperform)Total Votes: 469MarketBeat's community ratings are surveys of what our community members think about Mesoblast and other stocks. Vote "Outperform" if you believe MESO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MESO will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/19/2019 by MarketBeat.com StaffFeatured Article: Stock Symbol Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.